Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease

Background Crohn’s disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic and unpredictable, with a marked disconnect between symptoms and intestinal inflammation. Attempts to classify inflammatory bowel disease (IBD) subphenotypes to inform clinical decision making have been limited. We aimed to describe the latent disease heterogeneity by modelling routinely collected faecal calprotectin (FC) and CRP data, describing dynamic longitudinal inflammatory patterns in IBD.

Methods In this retrospective study, we analysed patient-level longitudinal measurements of FC and CRP recorded within seven years since diagnosis. Latent class mixed models (LCMMs) were used to cluster individuals with similar longitudinal FC or CRP profiles. Associations between cluster assignment and information available at diagnosis (e.g. age, sex, and Montreal classification) were quantified using multinomial logistic regression. Differences in advanced therapy use across clusters were also explored using cumulative distributions over time. Finally, we considered uncertainty in cluster assignments with respect to follow-up length and explored the overlap between clusters identified based on FC and CRP.

Findings We included 1036 patients (544 CD, 380 UC, 112 IBD-unclassified (IBDU)) in the FC analysis with a total of 10545 FC observations (median 9 per subject, IQR 6–13). The CRP analysis consisted of 1838 patients (805 CD, 847 UC, 186 IBDU) with 49364 CRP measurements (median 20 per subject; IQR 10–36). Eight distinct clusters of inflammatory behaviour over time were identified by LCMM in each analysis. The clusters, FC1-8 and CRP1-8, were ordered from the lowest cumulative inflammatory burden to the highest. The clusters included groups with high diagnostic levels of inflammation which rapidly normalised, groups where high inflammation levels persisted throughout the full seven years of observation, and a series of intermediates including delayed remitters and relapsing remitters.

CD and UC patients were unevenly distributed across the clusters. In CD, whilst patients with upper GI involvement (L4) were less likely to be in FC1 and FC2, there was no impact on ileal versus colonic disease on cluster assignment. In UC, male sex was associated with the poorest prognostic cluster (FC8). The use and timing of advanced therapy was associated with cluster assignment, with the highest use of early advanced therapy in FC1. Of note, FC8 and CRP8 captured consistently high patterns of inflammation despite a high proportion of patients receiving advanced therapy, particularly for CD individuals (56.8% and 33.3%, respectively). We observed that uncertainty in cluster assignments was higher for individuals with short longitudinal follow-up, particularly between clusters capturing similar earlier inflammation patterns. There was broadly poor agreement between FC and CRP clusters in keeping with the need to monitor both in clinical practice.

Interpretation Distinct patterns of inflammatory behaviour over time are evident in patients with IBD. Cluster assignment is associated with disease type and both the use and timing of advanced therapy. These data pave the way for a deeper understanding of disease heterogeneity in IBD and enhanced patient stratification in the clinic.